Study of KBP-7072 in Healthy Male and Female Subjects

Healthy Subjects Clinical Trial

Official title:

A Phase I, Double-blind, Placebo-controlled, Single and Multiple Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study of KBP-7072 in Healthy Male and Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05507463
• Other study ID #: KBP7072-1-004
• Status: Completed
• Phase: Phase 1
• Start date: August 16, 2022
• Est. completion date: June 29, 2023

Study information

• Verified date: February 2024
• Source: KBP Biosciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, randomized, placebo-controlled, single and multiple IV dose study conducted in two parts. Part A (SAD) will comprise an ascending single dose, sequential group design. Each subject will participate in 1 treatment period only. Subjects will reside at the study site from check-in on Day -1 (the day before dosing) to discharge on Day 8. In Part A, serial blood and urine collections will be obtained on Day 1 pre-dose through 168 hours post start of infusion for analysis of plasma and urine concentrations of KBP-7072 and KBP-6079. Safety will be monitored through recording of adverse events, clinical laboratory evaluations, vital sign measurements, 12-lead ECG and physical examination findings. Part B (MAD) will comprise an ascending multiple dose, sequential group study. Each subject will participate on one treatment period only and reside at the study site from check-in on Day -1 until discharge on Day 17. In Part B, serial blood and urine collections will be obtained on Day 1 pre-dose through 24 hours post start of infusion and on Day 10 pre-dose through 168 hours post start of infusion for analysis of plasma and urine concentrations of KBP-7072 and KBP-6079. Trough blood sample collections for analysis of plasma concentrations of KBP-7072 and KBP-6079 will be obtained pre-dose on Days 3, 4, 5, 6, 7, 8 and 9. Safety will be monitored through recording of adverse events, clinical laboratory evaluations, vital sign measurements, 12-lead ECG and physical examination findings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: June 29, 2023
• Est. primary completion date: June 29, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• BMI between 18 and 30 kg/m2 at the time of screening

• In good health, determined b no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements and clinical laboratory evaluations

• Females of nonchildbearing potential defined as permanently sterile or postmenopausal.

Males will agree to use contraception.

Exclusion Criteria:

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine or psychiatric disorder as determined by the investigator.

• Abnormal results of ophthalmologic examination within 3 months prior to dosing self-reported by subject.

• Supine systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg.

• Triglycerides > 200 mg/dL

• Total cholesterol > 240 mg/dL or LDL >190 mg/dL or HDL < 40 mg/dL

• Positive urine drug screen at screening or check-in or positive blood alcohol test result at check-in.

• Positive hepatitis panel and/or positive HIV test

• Administration of a Covid-19 vaccine in the past 28 days prior to dosing

• Interpretation of liver ultrasound with presence of fatty liver disease

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• KBP-7072
KBP-7072
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Parexel International - Early Phase Clinical Unit	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
KBP Biosciences	Parexel

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations	Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.	Time Frame: SAD 1- 7 days and MAD 1-17 days
Secondary	Pharmacokinetics Parameters :AUC from time 0 extrapolated to infinity (AUC0-8)	AUC from time 0 extrapolated to infinity (AUC0-8)	SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion
Secondary	Pharmacokinetics Parameters: Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC0-tlast),	Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma	SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion
Secondary	Pharmacokinetics Parameters: AUC over a dosing interval (AUC0-t), from time zero to time of last quantifiable concentration (AUC0-tlast)from time zero to time of last quantifiable concentration (AUC0-tlast)	AUC over a dosing interval (AUC0-t) - Plasma	MAD samples will be collected on Day 1 pre-dose and at 5, 15, 30, 45 minutes, and at 1, 1.5, 2, 4, 6, 10, 12, 24 (Day 2) hours, pre-dose samples at 48 (Day 3), 72 (Day 4), 96 (Da
Secondary	Pharmacokinetics Parameters: Maximum observed plasma concentration (Cmax)	Maximum observed plasma concentration (Cmax) - Plasma	SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion
Secondary	Pharmacokinetics Parameters: time of the maximum observed plasma concentration (Tmax)	Time of the maximum observed plasma concentration (Tmax) - Plasma	SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion
Secondary	Pharmacokinetics Parameters: apparent terminal elimination half-life (t1/2)	Apparent terminal elimination half-life (t1/2) - Plasma	SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168(Day 8) hour(s) post start of infusion
Secondary	Pharmacokinetics Parameters: observed accumulation ratio based on AUC0-t (ARAUC0-t)	Observed accumulation ratio based on AUC0-t (ARAUC0-t) - Plasma	MAD samples will be collected on Day 1 pre-dose and at 5, 15, 30, 45 minutes, and at 1, 1.5, 2, 4, 6, 10, 12, 24 (Day 2) hours, pre-dose samples at 48 (Day 3), 72 (Day 4), 96 (Da
Secondary	Pharmacokinetics Parameters: amount of drug excreted in urine (Ae)	Amount of drug excreted in urine (Ae) - Urine	SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168(Day 8) hour(s) post start of infusion